Brucine-Loaded Ethosomal Gel: Design, Optimization, and Anti-inflammatory Activity
Brucine, one of the natural medications obtained from Nux vomica seeds, is used as an anti-inflammatory drug. Several investigations were performed to overcome its drawbacks, which will affect significantly its pharmaceutical formulation. The goal of the current investigation was to design, optimize...
Saved in:
Published in | AAPS PharmSciTech Vol. 22; no. 8; p. 269 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
11.11.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Brucine, one of the natural medications obtained from Nux vomica seeds, is used as an anti-inflammatory drug. Several investigations were performed to overcome its drawbacks, which will affect significantly its pharmaceutical formulation. The goal of the current investigation was to design, optimize, and evaluate the anti-inflammatory performance of BRU ethosomal gel. Brucineethosomal formulations were prepared using thin film hydration method and optimized by central composite design approach using three independent variables (lecithin concentration, cholesterol concentration, and ethanol percentage) and three response variables (vesicular size, encapsulation efficiency, and skin permeation). The optimized formulation was examined for its stability and then incorporated into HPMC gel to get BRU ethosomal gel. The obtained BRU-loaded ethosomal gel was evaluated for its physical properties,
in
vitro
release, and
ex
vivo
permeation and skin irritation. Finally, carrageenan-induced rat hind paw edema test was adopted for the anti-inflammatory activity. The developed BRU ethosomal gel exhibited good physical characteristics comparable with the conventional developed BRU gel.
In
vitro
release of BRU from ethosomal gel was effectively extended for 6 h. Permeation of BRU from ethosomes was significantly higher than all formulations (
p
< 0.05), since it recorded steady state transdermal flux value 0.548 ± 0.03 μg/cm
2
h with enhancement ratio 2.73 ± 0.23. Eventually, BRU ethosomal gel exhibited potent anti-inflammatory activity as manifested by a significant decrease in rat hind paw inflammation following 24 h. In conclusion, the study emphasized the prospective of ethosomal gel as a fortunate carrier for intensifying the anti-inflammatory effect of Brucine. |
---|---|
AbstractList | Brucine, one of the natural medications obtained from Nux vomica seeds, is used as an anti-inflammatory drug. Several investigations were performed to overcome its drawbacks, which will affect significantly its pharmaceutical formulation. The goal of the current investigation was to design, optimize, and evaluate the anti-inflammatory performance of BRU ethosomal gel. Brucineethosomal formulations were prepared using thin film hydration method and optimized by central composite design approach using three independent variables (lecithin concentration, cholesterol concentration, and ethanol percentage) and three response variables (vesicular size, encapsulation efficiency, and skin permeation). The optimized formulation was examined for its stability and then incorporated into HPMC gel to get BRU ethosomal gel. The obtained BRU-loaded ethosomal gel was evaluated for its physical properties, in vitro release, and ex vivo permeation and skin irritation. Finally, carrageenan-induced rat hind paw edema test was adopted for the anti-inflammatory activity. The developed BRU ethosomal gel exhibited good physical characteristics comparable with the conventional developed BRU gel. In vitro release of BRU from ethosomal gel was effectively extended for 6 h. Permeation of BRU from ethosomes was significantly higher than all formulations (p < 0.05), since it recorded steady state transdermal flux value 0.548 ± 0.03 μg/cm2 h with enhancement ratio 2.73 ± 0.23. Eventually, BRU ethosomal gel exhibited potent anti-inflammatory activity as manifested by a significant decrease in rat hind paw inflammation following 24 h. In conclusion, the study emphasized the prospective of ethosomal gel as a fortunate carrier for intensifying the anti-inflammatory effect of Brucine.Brucine, one of the natural medications obtained from Nux vomica seeds, is used as an anti-inflammatory drug. Several investigations were performed to overcome its drawbacks, which will affect significantly its pharmaceutical formulation. The goal of the current investigation was to design, optimize, and evaluate the anti-inflammatory performance of BRU ethosomal gel. Brucineethosomal formulations were prepared using thin film hydration method and optimized by central composite design approach using three independent variables (lecithin concentration, cholesterol concentration, and ethanol percentage) and three response variables (vesicular size, encapsulation efficiency, and skin permeation). The optimized formulation was examined for its stability and then incorporated into HPMC gel to get BRU ethosomal gel. The obtained BRU-loaded ethosomal gel was evaluated for its physical properties, in vitro release, and ex vivo permeation and skin irritation. Finally, carrageenan-induced rat hind paw edema test was adopted for the anti-inflammatory activity. The developed BRU ethosomal gel exhibited good physical characteristics comparable with the conventional developed BRU gel. In vitro release of BRU from ethosomal gel was effectively extended for 6 h. Permeation of BRU from ethosomes was significantly higher than all formulations (p < 0.05), since it recorded steady state transdermal flux value 0.548 ± 0.03 μg/cm2 h with enhancement ratio 2.73 ± 0.23. Eventually, BRU ethosomal gel exhibited potent anti-inflammatory activity as manifested by a significant decrease in rat hind paw inflammation following 24 h. In conclusion, the study emphasized the prospective of ethosomal gel as a fortunate carrier for intensifying the anti-inflammatory effect of Brucine. Brucine, one of the natural medications obtained from Nux vomica seeds, is used as an anti-inflammatory drug. Several investigations were performed to overcome its drawbacks, which will affect significantly its pharmaceutical formulation. The goal of the current investigation was to design, optimize, and evaluate the anti-inflammatory performance of BRU ethosomal gel. Brucineethosomal formulations were prepared using thin film hydration method and optimized by central composite design approach using three independent variables (lecithin concentration, cholesterol concentration, and ethanol percentage) and three response variables (vesicular size, encapsulation efficiency, and skin permeation). The optimized formulation was examined for its stability and then incorporated into HPMC gel to get BRU ethosomal gel. The obtained BRU-loaded ethosomal gel was evaluated for its physical properties, in vitro release, and ex vivo permeation and skin irritation. Finally, carrageenan-induced rat hind paw edema test was adopted for the anti-inflammatory activity. The developed BRU ethosomal gel exhibited good physical characteristics comparable with the conventional developed BRU gel. In vitro release of BRU from ethosomal gel was effectively extended for 6 h. Permeation of BRU from ethosomes was significantly higher than all formulations ( p < 0.05), since it recorded steady state transdermal flux value 0.548 ± 0.03 μg/cm 2 h with enhancement ratio 2.73 ± 0.23. Eventually, BRU ethosomal gel exhibited potent anti-inflammatory activity as manifested by a significant decrease in rat hind paw inflammation following 24 h. In conclusion, the study emphasized the prospective of ethosomal gel as a fortunate carrier for intensifying the anti-inflammatory effect of Brucine. |
ArticleNumber | 269 |
Author | Abdallah, Marwa H. Elghamry, Hanaa A. Unissa, Rahamat Lila, Amr S. Abu Elsewedy, Heba S. Soliman, Mahmoud S. |
Author_xml | – sequence: 1 givenname: Marwa H. surname: Abdallah fullname: Abdallah, Marwa H. email: mh.abdallah@uoh.edu.sa organization: Department of Pharmaceutics, College of Pharmacy, University of Ha’il, Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University – sequence: 2 givenname: Amr S. Abu surname: Lila fullname: Lila, Amr S. Abu organization: Department of Pharmaceutics, College of Pharmacy, University of Ha’il, Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University – sequence: 3 givenname: Rahamat surname: Unissa fullname: Unissa, Rahamat organization: Department of Pharmaceutics, College of Pharmacy, University of Ha’il – sequence: 4 givenname: Heba S. surname: Elsewedy fullname: Elsewedy, Heba S. organization: Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University – sequence: 5 givenname: Hanaa A. surname: Elghamry fullname: Elghamry, Hanaa A. organization: Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University – sequence: 6 givenname: Mahmoud S. surname: Soliman fullname: Soliman, Mahmoud S. organization: Department of Pharmaceutics, College of Pharmacy, University of Ha’il, Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University |
BookMark | eNp9kE1LAzEQhoMo2Fb_gKc9ejCaj9028VZrrUKhIL2HbJKtKbtJTbJC_fVuux7EQw_DzMD7zMAzBOfOOwPADUb3mCD2EDEhOYeI4ENhCtkZGOCCIsg5Jed_5kswjHGLEKGY0wF4fwqtss7ApZfa6GyePnz0jayzhakfs2cT7cbdZatdso39lsn6bpNOZ1OXLLSuqmXTyOTDPpuqZL9s2l-Bi0rW0Vz_9hFYv8zXs1e4XC3eZtMlVJTkCWJJGKNjNDEV4oTnJS1UXiIqSYUUK5nWsuIlZ0jzAmFWEWMUURNOdFlMdElH4LY_uwv-szUxicZGZepaOuPbKEjBx3kxRgXuoqSPquBjDKYSu2AbGfYCI3HwJ3p_onMnjv4E6yD2D1I2HQWkIG19GqU9Grs_bmOC2Po2uE7GKeoHhp6GrA |
CitedBy_id | crossref_primary_10_3390_plants12213670 crossref_primary_10_1021_acsomega_4c01133 crossref_primary_10_3390_polym15030677 crossref_primary_10_3390_pr11061836 crossref_primary_10_3390_gels7040219 crossref_primary_10_3390_pharmaceutics15112521 crossref_primary_10_1371_journal_pone_0267257 crossref_primary_10_3390_pharmaceutics15031027 crossref_primary_10_3390_gels10080525 crossref_primary_10_2174_0115680096274284231116104554 crossref_primary_10_1007_s10876_023_02479_8 crossref_primary_10_3390_gels9020137 crossref_primary_10_3390_polym14030508 crossref_primary_10_3390_gels8070395 crossref_primary_10_1016_j_phyplu_2023_100490 crossref_primary_10_3390_polym14132637 crossref_primary_10_3390_gels8110737 crossref_primary_10_3390_life12071011 crossref_primary_10_1016_j_jddst_2025_106807 crossref_primary_10_1016_j_jddst_2022_103322 crossref_primary_10_3390_gels9060494 crossref_primary_10_3390_gels8050262 crossref_primary_10_1016_j_ejps_2023_106664 crossref_primary_10_1016_j_jsps_2023_101734 |
Cites_doi | 10.1016/S0168-3659(99)00222-9 10.3390/polym13040577 10.1016/j.colsurfa.2020.125618 10.3390/polym13050791 10.1016/j.ijpharm.2020.119278 10.3390/pharmaceutics12050446 10.1016/s0378-8741(03)00224-1 10.1016/j.ijpharm.2009.12.040 10.1016/j.nano.2010.01.002 10.3109/10717544.2013.860502 10.3389/fphar.2020.00377 10.1016/j.ejps.2014.09.014 10.1080/10717544.2019.1682720 10.2147/IJN.S105016 10.1016/j.ajps.2019.05.001 10.3390/ijms18040757 10.1208/pt070488 10.1016/j.jddst.2017.11.005 10.1016/j.ultsonch.2011.07.001 10.1002/jps.10200 10.3109/10717544.2013.861883 10.1016/j.biopha.2017.01.164 10.1016/S1773-2247(12)50059-6 10.3390/app10155341 10.1080/10717544.2020.1797237 10.4103/0110-5558.72415 10.1016/j.ejpb.2012.05.011 10.1155/2014/468456 10.1007/s10856-009-3773-6 10.1016/j.ijpharm.2006.12.005 10.1155/2017/8310979 10.1213/ANE.0b013e3182937b74 10.3109/03639045.2012.746360 10.3390/pharmaceutics12020151 10.2146/ajhp110158 10.1016/B978-0-12-815799-2.00019-8 10.1016/j.jddst.2019.05.048 10.3390/pharmaceutics11110609 10.1016/S0142-9612(01)00052-7 10.1007/s40199-019-00242-x 10.1155/2016/7394685 10.1186/s43094-019-0015-8 10.1016/j.foodchem.2017.02.051 10.1016/j.jconrel.2015.10.049 10.1208/s12248-014-9598-3 10.3390/plants10040735 10.1186/s12944-019-1064-x 10.18178/ijpmbs.10.1.23-29 10.5138/ijdd.2010.0975.0215.02016 10.3390/pharmaceutics11050230 10.3390/pharmaceutics9030033 |
ContentType | Journal Article |
Copyright | American Association of Pharmaceutical Scientists 2021 2021. American Association of Pharmaceutical Scientists. |
Copyright_xml | – notice: American Association of Pharmaceutical Scientists 2021 – notice: 2021. American Association of Pharmaceutical Scientists. |
DBID | AAYXX CITATION 7X8 |
DOI | 10.1208/s12249-021-02113-8 |
DatabaseName | CrossRef MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1530-9932 |
ExternalDocumentID | 10_1208_s12249_021_02113_8 |
GroupedDBID | --- -56 -5G -BR -EM -~C .86 .VR 06C 06D 0R~ 0VY 1N0 203 23M 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2~H 30V 406 408 40D 40E 53G 5GY 5VS 67N 6J9 6NX 875 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AAKDD AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHLI ABHQN ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABWNU ABXPI ACAOD ACDTI ACGFO ACGFS ACHSB ACKNC ACMDZ ACMJI ACMLO ACOKC ACOMO ACPIV ACREN ACSNA ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADURQ ADYFF ADYOE ADZKW AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFLOW AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHKAY AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJRNO AJZVZ AKMHD ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ AXYYD B-. BA0 BAWUL BGNMA CS3 CSCUP DDRTE DIK DNIVK DPUIP E3Z EBLON EBS EIOEI EMOBN ESBYG F5P FERAY FFXSO FIGPU FNLPD FRRFC FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 HG6 HH5 HMJXF HRMNR IJ- IKXTQ IWAJR IXC IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV KPH LLZTM M4Y MA- NPVJJ NQJWS NU0 O93 O9I O9J OK1 P2P PF0 PT4 QOR QOS R89 R9I ROL RPM RPX RSV S16 S27 S3A S3B SAP SBL SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZN T13 TR2 TSG TSV TUC U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 XSB YLTOR Z45 Z7U Z7V Z7W Z7X Z81 Z87 ZMTXR ZOVNA ~A9 -Y2 2VQ 4.4 AANXM AAPKM AARHV AAYXX ABBRH ABDBE ABFSG ABULA ACBXY ACMFV ACSTC AEBTG AEKMD AEZWR AFDZB AFGCZ AFHIU AFOHR AGJBK AHPBZ AHSBF AHWEU AIXLP AJBLW AOIJS ATHPR AYFIA BDATZ BSONS C1A CAG CITATION COF EJD EN4 FINBP FSGXE GX1 H13 HYE HZ~ LGEZI LOTEE NADUK NXXTH O9- OVD S1Z TEORI 7X8 |
ID | FETCH-LOGICAL-c324t-1a2883607ef09294b35c4b03a2f0c8b8ddaf9b980d95018f2eec2c792db57db3 |
IEDL.DBID | U2A |
ISSN | 1530-9932 |
IngestDate | Fri Jul 11 00:12:53 EDT 2025 Tue Jul 01 01:55:52 EDT 2025 Thu Apr 24 23:10:08 EDT 2025 Fri Feb 21 02:46:57 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Transdermal drug delivery Brucine Anti-inflammatory Ethosomes Gel |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c324t-1a2883607ef09294b35c4b03a2f0c8b8ddaf9b980d95018f2eec2c792db57db3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PQID | 2596456051 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_2596456051 crossref_primary_10_1208_s12249_021_02113_8 crossref_citationtrail_10_1208_s12249_021_02113_8 springer_journals_10_1208_s12249_021_02113_8 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-11-11 |
PublicationDateYYYYMMDD | 2021-11-11 |
PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-11 day: 11 |
PublicationDecade | 2020 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham |
PublicationSubtitle | An Official Journal of the American Association of Pharmaceutical Scientists |
PublicationTitle | AAPS PharmSciTech |
PublicationTitleAbbrev | AAPS PharmSciTech |
PublicationYear | 2021 |
Publisher | Springer International Publishing |
Publisher_xml | – name: Springer International Publishing |
References | Khedr, Shehata, Mohamed (CR35) 2014; 65 Shen, Ling, Jiang, Du, Lu, Tu (CR49) 2015; 22 Wu, Liang, Feng, Li, Yang, Liang, Tang, Shuai (CR3) 2017; 18 Wang, Yuan, Liu, Zhu, Shen, Yang (CR4) 2009; 20 Zhu, Li, Peng, Zeng (CR43) 2013; 117 Sakdiset, Amnuaikit, Pichayakorn, Pinsuwan (CR18) 2019; 52 Yu, Amidon, Khan, Hoag, Polli, Raju, Woodcock (CR15) 2014; 16 Lin, Lin, Choi, Michniak-Kohn (CR10) 2020; 581 Fathalla, Youssef, Soliman (CR45) 2020; 12 Sathyamoorthy, Magharla, Chintamaneni, Vankayalu (CR39) 2017; 6 Pathan, Jaware, Shelke, Ambekar (CR20) 2018; 44 Mao, Chen, Xu, Shen, Ye, Chaurasiya, Liu, Li, Xing, Chen (CR8) 2019; 26 Rahman, Zidan, Habib, Khan (CR14) 2010; 389 Soliman, Shehata, Mohamed, Younis, Elsewedy (CR27) 2021; 13 Elsewedy, Dhubiab, Mahdy, Elnahas (CR1) 2020; 27 Elsayed, Abdallah, Naggar, Khalafallah (CR9) 2007; 332 Sarigüllü Ozgüney, Yeşim Karasulu, Kantarci, Sözer, Güneri, Ertan (CR37) 2006; 7 Dantas, Reis, Damasceno, Rolim, Rolim-Neto, Carvalho, Quintans-Junior, da Silva Almeida (CR31) 2016; 2016 Yin, Wang, Yin, Cai (CR36) 2003; 88 CR5 Shehata, Nair, Al-Dhubiab, Shah, Jacob, Alhaider, Attimarad, Elsewedy, Ibrahim (CR26) 2020; 10 CR47 CR46 Limsuwan, Boonme, Khongkow, Amnuaikit (CR11) 2017; 2017 Galatage, Hebalkar, Gote, Mali, Killedar, Bhagwat, Kumbhar (CR33) 2020; 6 Tang, Manickam, Wei, Nashiru (CR17) 2012; 19 Shah, Nair, Shah, Jacob, Shehata, Morsy (CR19) 2020; 15 Touitou, Godin, Dayan, Weiss, Piliponsky, Levi-Schaffer (CR51) 2001; 22 Lu, Huang, Wu, Jin, Chen, Zhang, Luan (CR2) 2020; 11 Shah, Nair, Shah, Bharadia, Al-Dhubiab (CR50) 2019; 27 Elsewedy, Aldhubiab, Mahdy, Elnahas (CR32) 2021; 608 Khalil, Alqahtani, Darrag, Ibrahim, Emeka, Badger-Emeka, Matsunami, Shehata, Elsewedy (CR21) 2021; 10 Nayak, Ahmed, Beg, Tabish, Hasnain, Beg, Hasnain (CR13) 2019 Dubey, Mishra, Nahar, Jain, Jain (CR42) 2010; 6 Touitou, Dayan, Bergelson, Godin, Eliaz (CR44) 2000; 65 Arora, Aggarwal, Harikumar, Kaur (CR30) 2014; 2014 Ibrahim, Ahmed, Hussain, Rahman, Samy, Kaseem, Nutan (CR38) 2014; 40 Arora, Mukherjee (CR34) 2002; 91 Li, Wang, Wang (CR16) 2017; 229 Shehata, Ibrahim, Elsewedy (CR29) 2021; 13 Nandini, Doijad, Shivakumar, Dandagi (CR41) 2015; 22 Ahad, Al-Saleh, Al-Mohizea, Al-Jenoobi, Raish, Yassin, Alam (CR48) 2017; 89 Li, Fan, Fan, Li, Wang, Li, Liu (CR52) 2012; 82 Ibrahim, Shehata (CR23) 2012; 22 CR25 Bolla, Clark, Juluri, Cheruvu, Renukuntla (CR53) 2020; 12 CR24 Verma, Pathak (CR12) 2010; 1 CR22 Morsy, Abdel-Latif, Nair, Venugopala, Ahmed, Elsewedy, Shehata (CR28) 2019; 11 Abdulbaqi, Darwis, Khan, Assi, Khan (CR40) 2016; 11 Goyal, Macri, Kaplan, Kohn (CR6) 2016; 240 Durand, Alhammad, Willett (CR7) 2012; 69 P Sakdiset (2113_CR18) 2019; 52 T Limsuwan (2113_CR11) 2017; 2017 PK Bolla (2113_CR53) 2020; 12 HE Khalil (2113_CR21) 2021; 10 I Sarigüllü Ozgüney (2113_CR37) 2006; 7 LX Yu (2113_CR15) 2014; 16 P Verma (2113_CR12) 2010; 1 J Wang (2113_CR4) 2009; 20 P Arora (2113_CR34) 2002; 91 MM Elsayed (2113_CR9) 2007; 332 TM Shehata (2113_CR26) 2020; 10 2113_CR24 HS Elsewedy (2113_CR32) 2021; 608 HM Ibrahim (2113_CR38) 2014; 40 X Zhu (2113_CR43) 2013; 117 2113_CR22 2113_CR5 E Touitou (2113_CR44) 2000; 65 PT Nandini (2113_CR41) 2015; 22 Y Mao (2113_CR8) 2019; 26 TM Shehata (2113_CR29) 2021; 13 W Yin (2113_CR36) 2003; 88 2113_CR25 ST Galatage (2113_CR33) 2020; 6 C Durand (2113_CR7) 2012; 69 Y Shen (2113_CR49) 2015; 22 MA Morsy (2113_CR28) 2019; 11 R Arora (2113_CR30) 2014; 2014 H Shah (2113_CR50) 2019; 27 IM Abdulbaqi (2113_CR40) 2016; 11 P Wu (2113_CR3) 2017; 18 SY Tang (2113_CR17) 2012; 19 R Goyal (2113_CR6) 2016; 240 Z Rahman (2113_CR14) 2010; 389 HS Elsewedy (2113_CR1) 2020; 27 AK Nayak (2113_CR13) 2019 A Ahad (2113_CR48) 2017; 89 X Li (2113_CR16) 2017; 229 E Touitou (2113_CR51) 2001; 22 J Shah (2113_CR19) 2020; 15 MA Khedr (2113_CR35) 2014; 65 H Lin (2113_CR10) 2020; 581 2113_CR46 IB Pathan (2113_CR20) 2018; 44 G Li (2113_CR52) 2012; 82 N Sathyamoorthy (2113_CR39) 2017; 6 WE Soliman (2113_CR27) 2021; 13 D Fathalla (2113_CR45) 2020; 12 L Lu (2113_CR2) 2020; 11 2113_CR47 MGB Dantas (2113_CR31) 2016; 2016 MM Ibrahim (2113_CR23) 2012; 22 V Dubey (2113_CR42) 2010; 6 |
References_xml | – ident: CR22 – volume: 65 start-page: 403 year: 2000 end-page: 418 ident: CR44 article-title: Ethosomes—novel vesicular carriers for enhanced delivery: characterization and skin penetration properties publication-title: J Control Release doi: 10.1016/S0168-3659(99)00222-9 – volume: 13 start-page: 577 year: 2021 ident: CR27 article-title: Enhancement of curcumin anti-inflammatory effect via formulation into myrrh oil-based nanoemulgel publication-title: Polymers doi: 10.3390/polym13040577 – volume: 6 start-page: 362 year: 2017 end-page: 373 ident: CR39 article-title: Optimization of paclitaxel loaded poly (ε-caprolactone) nanoparticles using Box Behnken design publication-title: Beni-Suef Univ J Basic Appl Sci – volume: 608 start-page: 125618 year: 2021 ident: CR32 article-title: Brucine PEGylated nanoemulsion: in vitro and in vivo evaluation publication-title: Colloids Surf A Physicochem Eng Asp doi: 10.1016/j.colsurfa.2020.125618 – volume: 13 start-page: 791 year: 2021 ident: CR29 article-title: Curcumin niosomes prepared from proniosomal gels: in vitro skin permeability, kinetic and in vivo studies publication-title: Polymers doi: 10.3390/polym13050791 – ident: CR25 – volume: 581 start-page: 119278 year: 2020 ident: CR10 article-title: Development and in-vitro evaluation of co-loaded berberine chloride and evodiamine ethosomes for treatment of melanoma publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2020.119278 – volume: 12 start-page: 446 year: 2020 ident: CR45 article-title: Liposomal and ethosomal gels for the topical delivery of anthralin: preparation, comparative evaluation and clinical assessment in psoriatic patients publication-title: Pharmaceutics doi: 10.3390/pharmaceutics12050446 – volume: 88 start-page: 205 year: 2003 end-page: 214 ident: CR36 article-title: Analgesic and anti-inflammatory properties of brucine and brucine N-oxide extracted from seeds of Strychnos nux-vomica publication-title: J Ethnopharmacol doi: 10.1016/s0378-8741(03)00224-1 – volume: 389 start-page: 186 year: 2010 end-page: 194 ident: CR14 article-title: Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2009.12.040 – volume: 6 start-page: 590 year: 2010 end-page: 596 ident: CR42 article-title: Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes publication-title: Nanomed Nanotechnol Biol Med doi: 10.1016/j.nano.2010.01.002 – ident: CR46 – volume: 22 start-page: 647 year: 2015 end-page: 651 ident: CR41 article-title: Formulation and evaluation of gemcitabine-loaded solid lipid nanoparticles publication-title: Drug Deliv doi: 10.3109/10717544.2013.860502 – volume: 11 start-page: 377 year: 2020 ident: CR2 article-title: Brucine: a review of phytochemistry, pharmacology, and toxicology publication-title: Front Pharmacol doi: 10.3389/fphar.2020.00377 – volume: 65 start-page: 130 year: 2014 end-page: 138 ident: CR35 article-title: Repositioning of 2,4-Dichlorophenoxy acetic acid as a potential anti-inflammatory agent: In Silico and Pharmaceutical Formulation study publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2014.09.014 – volume: 26 start-page: 1104 year: 2019 end-page: 1114 ident: CR8 article-title: Eprinomectin nanoemulgel for transdermal delivery against endoparasites and ectoparasites: preparation, in vitro and in vivo evaluation publication-title: Drug Deliv doi: 10.1080/10717544.2019.1682720 – volume: 11 start-page: 2279 year: 2016 end-page: 2304 ident: CR40 article-title: Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials publication-title: Int J Nanomed doi: 10.2147/IJN.S105016 – volume: 15 start-page: 786 year: 2020 end-page: 796 ident: CR19 article-title: Enhancement in antinociceptive and anti-inflammatory effects of tramadol by transdermal proniosome gel publication-title: Asian J Pharm Sci doi: 10.1016/j.ajps.2019.05.001 – volume: 18 start-page: 757 year: 2017 ident: CR3 article-title: A novel brucine gel transdermal delivery system designed for anti-inflammatory and analgesic activities publication-title: Int J Mol Sci doi: 10.3390/ijms18040757 – volume: 7 start-page: 88 year: 2006 ident: CR37 article-title: Transdermal delivery of diclofenac sodium through rat skin from various formulations publication-title: AAPS PharmSciTech doi: 10.1208/pt070488 – ident: CR5 – volume: 44 start-page: 49 year: 2018 end-page: 57 ident: CR20 article-title: Curcumin loaded ethosomes for transdermal application: frmulation, optimization, in-vitro and in-vivo study publication-title: J Drug Delivery Sci Technol doi: 10.1016/j.jddst.2017.11.005 – volume: 19 start-page: 330 year: 2012 end-page: 345 ident: CR17 article-title: Formulation development and optimization of a novel Cremophore EL-based nanoemulsion using ultrasound cavitation publication-title: Ultrason Sonochem doi: 10.1016/j.ultsonch.2011.07.001 – volume: 91 start-page: 2076 year: 2002 end-page: 2089 ident: CR34 article-title: Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt publication-title: J Pharm Sci doi: 10.1002/jps.10200 – volume: 22 start-page: 911 year: 2015 end-page: 917 ident: CR49 article-title: Formulation and evaluation of Cyclosporin A emulgel for ocular delivery publication-title: Drug Deliv doi: 10.3109/10717544.2013.861883 – volume: 89 start-page: 177 year: 2017 end-page: 184 ident: CR48 article-title: Pharmacodynamic study of eprosartan mesylate-loaded transfersomes Carbopol(®) gel under Dermaroller(®) on rats with methyl prednisolone acetate-induced hypertension publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2017.01.164 – volume: 22 start-page: 353 year: 2012 end-page: 359 ident: CR23 article-title: The enhancement of transdermal permeability of water soluble drug by niosome-emulgel combination publication-title: J Drug Delivery Sci Technol doi: 10.1016/S1773-2247(12)50059-6 – volume: 10 start-page: 5341 year: 2020 ident: CR26 article-title: Vesicular emulgel based system for transdermal delivery of insulin: factorial design and in vivo evaluation publication-title: Appl Sci doi: 10.3390/app10155341 – ident: CR47 – volume: 27 start-page: 1134 year: 2020 end-page: 1146 ident: CR1 article-title: Development, optimization, and evaluation of PEGylated brucine-loaded PLGA nanoparticles publication-title: Drug Delivery doi: 10.1080/10717544.2020.1797237 – volume: 1 start-page: 274 year: 2010 ident: CR12 article-title: Therapeutic and cosmeceutical potential of ethosomes: an overview publication-title: J Adv Pharm Technol Res doi: 10.4103/0110-5558.72415 – volume: 82 start-page: 49 year: 2012 end-page: 57 ident: CR52 article-title: Tacrolimus-loaded ethosomes: physicochemical characterization and in vivo evaluation publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2012.05.011 – volume: 2014 start-page: 468456 year: 2014 ident: CR30 article-title: Nanoemulsion based hydrogel for enhanced transdermal delivery of ketoprofen publication-title: Adv Pharm doi: 10.1155/2014/468456 – volume: 20 start-page: 2075 year: 2009 end-page: 2084 ident: CR4 article-title: Preparation and pharmaceutical/pharmacodynamic evaluation of topical brucine-loaded liposomal hydrogel publication-title: J Mater Sci Mater Med doi: 10.1007/s10856-009-3773-6 – volume: 332 start-page: 1 year: 2007 end-page: 16 ident: CR9 article-title: Lipid vesicles for skin delivery of drugs: reviewing three decades of research publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2006.12.005 – volume: 2017 start-page: 8310979 year: 2017 ident: CR11 article-title: Ethosomes of phenylethyl resorcinol as vesicular delivery system for skin lightening applications publication-title: Biomed Res Int doi: 10.1155/2017/8310979 – volume: 117 start-page: 352 year: 2013 end-page: 357 ident: CR43 article-title: Formulation and evaluation of lidocaine base ethosomes for transdermal delivery publication-title: Anesth Analg doi: 10.1213/ANE.0b013e3182937b74 – volume: 40 start-page: 66 year: 2014 end-page: 73 ident: CR38 article-title: Development of meloxicam in situ implant formulation by quality by design principle publication-title: Drug Dev Ind Pharm doi: 10.3109/03639045.2012.746360 – volume: 12 start-page: 151 year: 2020 ident: CR53 article-title: Evaluation of formulation parameters on permeation of ibuprofen from topical formulations using Strat-M® membrane publication-title: Pharmaceutics doi: 10.3390/pharmaceutics12020151 – volume: 69 start-page: 116 year: 2012 end-page: 124 ident: CR7 article-title: Practical considerations for optimal transdermal drug delivery publication-title: Am J Health Syst Pharm doi: 10.2146/ajhp110158 – start-page: 399 year: 2019 end-page: 411 ident: CR13 article-title: Chapter 18 - Application of quality by design for the development of biopharmaceuticals publication-title: Pharmaceutical quality by design doi: 10.1016/B978-0-12-815799-2.00019-8 – volume: 52 start-page: 760 year: 2019 end-page: 768 ident: CR18 article-title: Formulation development of ethosomes containing indomethacin for transdermal delivery publication-title: J Drug Delivery Sci Technol doi: 10.1016/j.jddst.2019.05.048 – volume: 11 start-page: 609 year: 2019 ident: CR28 article-title: Preparation and evaluation of atorvastatin-loaded nanoemulgel on wound-healing efficacy publication-title: Pharmaceutics doi: 10.3390/pharmaceutics11110609 – volume: 22 start-page: 3053 year: 2001 end-page: 3059 ident: CR51 article-title: Intracellular delivery mediated by an ethosomal carrier publication-title: Biomaterials doi: 10.1016/S0142-9612(01)00052-7 – volume: 27 start-page: 59 year: 2019 end-page: 70 ident: CR50 article-title: Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats publication-title: Daru doi: 10.1007/s40199-019-00242-x – volume: 2016 start-page: 7394685 year: 2016 ident: CR31 article-title: Development and evaluation of stability of a gel formulation containing the monoterpene borneol publication-title: Sci World J doi: 10.1155/2016/7394685 – volume: 6 start-page: 1 year: 2020 end-page: 11 ident: CR33 article-title: Design and characterization of camptothecin gel for treatment of epidermoid carcinoma publication-title: Future J Pharm Sci doi: 10.1186/s43094-019-0015-8 – volume: 229 start-page: 479 year: 2017 end-page: 486 ident: CR16 article-title: Optimization of encapsulation efficiency and average particle size of Hohenbuehelia serotina polysaccharides nanoemulsions using response surface methodology publication-title: Food Chem doi: 10.1016/j.foodchem.2017.02.051 – volume: 240 start-page: 77 year: 2016 end-page: 92 ident: CR6 article-title: Nanoparticles and nanofibers for topical drug delivery publication-title: J Control Release doi: 10.1016/j.jconrel.2015.10.049 – ident: CR24 – volume: 16 start-page: 771 year: 2014 end-page: 783 ident: CR15 article-title: Understanding pharmaceutical quality by design publication-title: AAPS J doi: 10.1208/s12248-014-9598-3 – volume: 10 start-page: 735 year: 2021 ident: CR21 article-title: Date palm extract (Phoenix dactylifera) PEGylated nanoemulsion: development, optimization and cytotoxicity evaluation publication-title: Plants doi: 10.3390/plants10040735 – volume: 389 start-page: 186 year: 2010 ident: 2113_CR14 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2009.12.040 – volume: 7 start-page: 88 year: 2006 ident: 2113_CR37 publication-title: AAPS PharmSciTech doi: 10.1208/pt070488 – volume: 6 start-page: 1 year: 2020 ident: 2113_CR33 publication-title: Future J Pharm Sci doi: 10.1186/s43094-019-0015-8 – volume: 12 start-page: 151 year: 2020 ident: 2113_CR53 publication-title: Pharmaceutics doi: 10.3390/pharmaceutics12020151 – volume: 22 start-page: 353 year: 2012 ident: 2113_CR23 publication-title: J Drug Delivery Sci Technol doi: 10.1016/S1773-2247(12)50059-6 – volume: 27 start-page: 59 year: 2019 ident: 2113_CR50 publication-title: Daru doi: 10.1007/s40199-019-00242-x – volume: 117 start-page: 352 year: 2013 ident: 2113_CR43 publication-title: Anesth Analg doi: 10.1213/ANE.0b013e3182937b74 – ident: 2113_CR25 doi: 10.3390/pharmaceutics11110609 – volume: 27 start-page: 1134 year: 2020 ident: 2113_CR1 publication-title: Drug Delivery doi: 10.1080/10717544.2020.1797237 – volume: 65 start-page: 403 year: 2000 ident: 2113_CR44 publication-title: J Control Release doi: 10.1016/S0168-3659(99)00222-9 – volume: 89 start-page: 177 year: 2017 ident: 2113_CR48 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2017.01.164 – volume: 1 start-page: 274 year: 2010 ident: 2113_CR12 publication-title: J Adv Pharm Technol Res doi: 10.4103/0110-5558.72415 – volume: 11 start-page: 377 year: 2020 ident: 2113_CR2 publication-title: Front Pharmacol doi: 10.3389/fphar.2020.00377 – start-page: 399 volume-title: Pharmaceutical quality by design year: 2019 ident: 2113_CR13 doi: 10.1016/B978-0-12-815799-2.00019-8 – volume: 52 start-page: 760 year: 2019 ident: 2113_CR18 publication-title: J Drug Delivery Sci Technol doi: 10.1016/j.jddst.2019.05.048 – volume: 12 start-page: 446 year: 2020 ident: 2113_CR45 publication-title: Pharmaceutics doi: 10.3390/pharmaceutics12050446 – volume: 22 start-page: 3053 year: 2001 ident: 2113_CR51 publication-title: Biomaterials doi: 10.1016/S0142-9612(01)00052-7 – volume: 332 start-page: 1 year: 2007 ident: 2113_CR9 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2006.12.005 – volume: 15 start-page: 786 year: 2020 ident: 2113_CR19 publication-title: Asian J Pharm Sci doi: 10.1016/j.ajps.2019.05.001 – ident: 2113_CR47 doi: 10.1186/s12944-019-1064-x – volume: 88 start-page: 205 year: 2003 ident: 2113_CR36 publication-title: J Ethnopharmacol doi: 10.1016/s0378-8741(03)00224-1 – volume: 581 start-page: 119278 year: 2020 ident: 2113_CR10 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2020.119278 – volume: 44 start-page: 49 year: 2018 ident: 2113_CR20 publication-title: J Drug Delivery Sci Technol doi: 10.1016/j.jddst.2017.11.005 – volume: 91 start-page: 2076 year: 2002 ident: 2113_CR34 publication-title: J Pharm Sci doi: 10.1002/jps.10200 – volume: 6 start-page: 362 year: 2017 ident: 2113_CR39 publication-title: Beni-Suef Univ J Basic Appl Sci – volume: 229 start-page: 479 year: 2017 ident: 2113_CR16 publication-title: Food Chem doi: 10.1016/j.foodchem.2017.02.051 – volume: 2016 start-page: 7394685 year: 2016 ident: 2113_CR31 publication-title: Sci World J doi: 10.1155/2016/7394685 – ident: 2113_CR5 doi: 10.18178/ijpmbs.10.1.23-29 – volume: 82 start-page: 49 year: 2012 ident: 2113_CR52 publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2012.05.011 – volume: 19 start-page: 330 year: 2012 ident: 2113_CR17 publication-title: Ultrason Sonochem doi: 10.1016/j.ultsonch.2011.07.001 – volume: 13 start-page: 791 year: 2021 ident: 2113_CR29 publication-title: Polymers doi: 10.3390/polym13050791 – volume: 69 start-page: 116 year: 2012 ident: 2113_CR7 publication-title: Am J Health Syst Pharm doi: 10.2146/ajhp110158 – ident: 2113_CR46 doi: 10.5138/ijdd.2010.0975.0215.02016 – volume: 26 start-page: 1104 year: 2019 ident: 2113_CR8 publication-title: Drug Deliv doi: 10.1080/10717544.2019.1682720 – ident: 2113_CR24 doi: 10.3390/pharmaceutics11050230 – volume: 40 start-page: 66 year: 2014 ident: 2113_CR38 publication-title: Drug Dev Ind Pharm doi: 10.3109/03639045.2012.746360 – volume: 16 start-page: 771 year: 2014 ident: 2113_CR15 publication-title: AAPS J doi: 10.1208/s12248-014-9598-3 – volume: 20 start-page: 2075 year: 2009 ident: 2113_CR4 publication-title: J Mater Sci Mater Med doi: 10.1007/s10856-009-3773-6 – volume: 10 start-page: 5341 year: 2020 ident: 2113_CR26 publication-title: Appl Sci doi: 10.3390/app10155341 – volume: 11 start-page: 609 year: 2019 ident: 2113_CR28 publication-title: Pharmaceutics doi: 10.3390/pharmaceutics11110609 – volume: 240 start-page: 77 year: 2016 ident: 2113_CR6 publication-title: J Control Release doi: 10.1016/j.jconrel.2015.10.049 – volume: 2014 start-page: 468456 year: 2014 ident: 2113_CR30 publication-title: Adv Pharm doi: 10.1155/2014/468456 – volume: 22 start-page: 647 year: 2015 ident: 2113_CR41 publication-title: Drug Deliv doi: 10.3109/10717544.2013.860502 – volume: 65 start-page: 130 year: 2014 ident: 2113_CR35 publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2014.09.014 – volume: 22 start-page: 911 year: 2015 ident: 2113_CR49 publication-title: Drug Deliv doi: 10.3109/10717544.2013.861883 – volume: 6 start-page: 590 year: 2010 ident: 2113_CR42 publication-title: Nanomed Nanotechnol Biol Med doi: 10.1016/j.nano.2010.01.002 – volume: 18 start-page: 757 year: 2017 ident: 2113_CR3 publication-title: Int J Mol Sci doi: 10.3390/ijms18040757 – volume: 13 start-page: 577 year: 2021 ident: 2113_CR27 publication-title: Polymers doi: 10.3390/polym13040577 – volume: 11 start-page: 2279 year: 2016 ident: 2113_CR40 publication-title: Int J Nanomed doi: 10.2147/IJN.S105016 – volume: 608 start-page: 125618 year: 2021 ident: 2113_CR32 publication-title: Colloids Surf A Physicochem Eng Asp doi: 10.1016/j.colsurfa.2020.125618 – ident: 2113_CR22 doi: 10.3390/pharmaceutics9030033 – volume: 2017 start-page: 8310979 year: 2017 ident: 2113_CR11 publication-title: Biomed Res Int doi: 10.1155/2017/8310979 – volume: 10 start-page: 735 year: 2021 ident: 2113_CR21 publication-title: Plants doi: 10.3390/plants10040735 |
SSID | ssj0023193 |
Score | 2.4325197 |
Snippet | Brucine, one of the natural medications obtained from Nux vomica seeds, is used as an anti-inflammatory drug. Several investigations were performed to overcome... |
SourceID | proquest crossref springer |
SourceType | Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 269 |
SubjectTerms | Biochemistry Biomedical and Life Sciences Biomedicine Biotechnology Pharmacology/Toxicology Pharmacy Research Article |
Title | Brucine-Loaded Ethosomal Gel: Design, Optimization, and Anti-inflammatory Activity |
URI | https://link.springer.com/article/10.1208/s12249-021-02113-8 https://www.proquest.com/docview/2596456051 |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEA66e_EiPnF9LBFkLzbYpq_UW9FdF9_ILugpJE2KgtuK7R789076cFFE8NDbJIeZr5lvmBdCR04KXkR4IZEsgAAFDEuk8D3CRChNoyZ4UNM7fHMbjKfe5aP_2DSFFW21e5uSrF7qagKCzU4KkwOKiCkpgM9xCVtGXd_E7oDiKY2_wiwAldu0x_x-7rsLWvDKH6nQysOM1tBqQw1xXNtyHS3pbAMN7uvZ0h8WnixapQoLD_D9Yur0xyZ6MFYCykiuc6G0wsPyOS_yGVx4oV9P8XlVqWHhO3giZk3vpYVFpnCclS8EcAbQmFUpdxwn9UqJLTQZDSdnY9IsTCAJ8KKSOMLsDg7sUKc20B5Pun4C6ncFTe2ESaaUSCMZMVtFZo5fSrVOaBJGVEk_VNLdRp0sz_QOwl6gnUgoCI-p6yk4Ql3FJEjRSDOX2T3ktCrkSTNM3Oy0eOUmqAC181rtHFTOK7Vz1kPHX2fe6lEaf0oftpbhgHiTxhCZzucFh4AtANoHr0kPWa3JePPrFX9cufs_8T20Qg1qTM2fs4865ftcHwADKWUfdeOLp6thvwLeJwS7024 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEF60HvQiPrE-VxAvZjHZpMnGW9Fq1VqLtOBt2c1uUGgTMemh_97ZPFoUETzkNrOHmcnMN8wLoTMnhigivIBI5kOCAoolUrQ8wkQgzaAmRFAzO_zU97sj7-G19VoNhWV1t3tdkiw8dbEBwWaXmakBhcS0FMDnuIQtoxUAA8w0co1oe55mgVG51XjM73zfQ9ACV_4ohRYR5nYDrVfQELdLXW6iJZ1sofNBuVt6ZuHhYlQqs_A5Hiy2Ts-20YvREkBG0kuF0gp38rc0Syfw4J0eX-GbolPDws_gIibV7KWFRaJwO8nfCdgZmMakKLnjdlSelNhBw9vO8LpLqoMJJAJclBNHmNvBvh3o2AbY40m3FYH4XUFjO2KSKSXiUIbMVqHZ4xdTrSMaBSFVshUo6e6iRpImeg9hz9dOKBSkx9T1FLBQVzEJVDTUzGV2Ezm1CHlULRM3Ny3G3CQVIHZeip2DyHkhds6a6GLO81Gu0viT-rTWDAeLN2UMkeh0mnFI2HyAfeBNmsiqVcarXy_748n9_5GfoNXu8KnHe_f9xwO0Ro0Fmf4_5xA18s-pPgI0ksvjwvi-AH2N1M0 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS8MwEA86QXwRP3F-RhBfbFibdm3q29DNbx2ywd5C0qQobO2w9WH_vZe221Rk4ENfSpKHu0vud9zd7xA6c2LwIsILiGQ-BCigWCJF0yNMBNI0aoIHNb3DT8_-bd-7HzQH37r4i2r3aUqy7GkwLE1J3hiruGRDsFkjM_mgkJjyAvgcl7BltALPsWPsuk9bs5AL_rhVq8zf-366oznG_JUWLbxNZwOtVzARt0q9bqIlnWyh827JMz2xcG_eNpVZ-Bx35wzUk230ajQG8JE8pkJphdv5W5qlIzjwRg8v8XVRtWHhF3guRlUfpoVFonAryd8J2ByYyahIv-NWVI6X2EG9Trt3dUuq4QkkAoyUE0eYOcK-HejYBgjkSbcZgSpcQWM7YpIpJeJQhsxWoeH0i6nWEY2CkCrZDJR0d1EtSRO9h7DnaycUCkJl6noKtlBXMQmraKiZy-w6cqYi5FFFLG7mWwy5CTBA7LwUOweR80LsnNXRxWzPuKTVWLj6dKoZDtZvUhoi0elnxiF48wECwstSR9ZUZby6htmCI_f_t_wErXavO_zx7vnhAK1RY0CmFNA5RLX841MfATDJ5XFhe1_seNkJ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brucine-Loaded+Ethosomal+Gel%3A+Design%2C+Optimization%2C+and+Anti-inflammatory+Activity&rft.jtitle=AAPS+PharmSciTech&rft.au=Abdallah%2C+Marwa+H.&rft.au=Lila%2C+Amr+S.+Abu&rft.au=Unissa%2C+Rahamat&rft.au=Elsewedy%2C+Heba+S.&rft.date=2021-11-11&rft.issn=1530-9932&rft.eissn=1530-9932&rft.volume=22&rft.issue=8&rft_id=info:doi/10.1208%2Fs12249-021-02113-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1208_s12249_021_02113_8 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1530-9932&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1530-9932&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1530-9932&client=summon |